1. Home
  2. CCM vs CNSY Comparison

CCM vs CNSY Comparison

Compare CCM & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited

N/A

Current Price

$3.59

Market Cap

21.3M

Sector

Health Care

ML Signal

N/A

Logo Cerenome Inc. Common Stock

CNSY

Cerenome Inc. Common Stock

HOLD

Current Price

$0.71

Market Cap

20.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCM
CNSY
Founded
1997
1996
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.3M
20.6M
IPO Year
2009
2016

Fundamental Metrics

Financial Performance
Metric
CCM
CNSY
Price
$3.59
$0.71
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $27.75
AVG Volume (30 Days)
12.4K
★ 2.1M
Earning Date
11-27-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 87.61
EPS
★ N/A
N/A
Revenue
N/A
★ $5,213,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$339.01
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.79
$0.43
52 Week High
$6.80
$4.25

Technical Indicators

Market Signals
Indicator
CCM
CNSY
Relative Strength Index (RSI) 49.72 31.64
Support Level $3.28 N/A
Resistance Level $4.10 $2.28
Average True Range (ATR) 0.26 0.42
MACD -0.00 -0.03
Stochastic Oscillator 47.31 7.16

Price Performance

Historical Comparison
CCM
CNSY

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.

About CNSY Cerenome Inc. Common Stock

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Share on Social Networks: